Zimmer Biomet Holdings (ZBH) has announced its
financial results for Q4 and the full year of 2024, demonstrating strong revenue growth. The company has secured a definitive agreement to
acquire Paragon 28 for $1.1 billion, further boosting its portfolio. Despite a 23% loss for shareholders over the past five years, ZBH witnesses significant movements in stocks with various asset management and investment groups increasing or decreasing their holdings. A
dividend has been declared for Q4, reflecting the company's robust financial health. Notwithstanding hitting a new 12-month low, analysts and investors appear confident in ZBH’s prospects. The company has successfully received
CE Mark Certification for its Persona® Revision Knee System and has also launched the NeuroOne Alliance and Z1 Hip System. Despite an earnings miss in Q3, ZBH stock is still anticipated to gain support from market share gains amid macro issues.
Arnold Schwarzenegger has joined the company in a landmark partnership, and ZBH has also received FDA approval for the Oxford® Cementless Partial Knee, the only cementless partial knee replacement implant in the U.S.
Forecasting profit for 2025 may be below estimates, due to market challenges.
Zimmer Biomet Holdings ZBH News Analytics from Thu, 02 May 2024 07:00:00 GMT to Sat, 15 Feb 2025 05:40:27 GMT -
Rating 2
- Innovation 6
- Information 8
- Rumor -4
